The latest price target for Avidity Biosciences (NASDAQ:RNA) was reported by RBC Capital on January 21, 2025. The analyst firm set a price target for $67.00 expecting RNA to rise to within 12 months (a possible 104.35% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Avidity Biosciences (NASDAQ:RNA) was provided by RBC Capital, and Avidity Biosciences reiterated their outperform rating.

The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.

The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on January 21, 2025 so you should expect the next rating to be made available sometime around January 21, 2026.

While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a reiterated with a price target of $67.00 to $67.00. The current price Avidity Biosciences (RNA) is trading at is $32.79, which is out of the analyst’s predicted range.